/

LPCN

Lipocine Inc.Closed

1.62−0.04 −2.41%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.59 −1.78%

Open

1.64

Prev close

1.66

Day range

1.611.73

52-week range

1.5912.37

Volume

498.72K0.28×

Mkt cap

13.36M

P/E ttm

—

Fwd P/E

-1.31

EPS ttm

-1.85

Div yield

0.00%

Earnings

—

From 52w high

−86.90%

Price Chart

Yahoo Finance · delayed

LPCNOct 13, 2026O 1.64H 1.74L 1.61C 1.62−0.04 (−2.41%)Vol 500.40K

SMA 502.13
SMA 2004.33

1Y change −47.91% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LPCN Lipocine Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −22.86%
1 month: −28.63%
3 months: −29.87%
6 months: −35.97%
Year to date: −79.83%
1 year: −47.91%

Valuation & ownership

Market cap: 13.36M
Enterprise value: −9.65M
P/E (ttm): —
Forward P/E: -1.31
PEG ratio: —
Price / book: 0.61
Price / sales (ttm): 8.51
EV / EBITDA: 0.77
EPS (ttm): -1.85
EPS (forward): -1.24
Beta (5y monthly): 0.40
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 8.24M
Float: 6.51M
Short % of float: 1.21%
Short ratio (days): 2.95
Held by insiders: 4.96%
Held by institutions: 36.19%
Avg volume (3m): 1.78M
50-day average: 2.14
200-day average: 4.34
52-week change: −47.91%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 26.4
vs 50-day SMA: −23.97%
vs 200-day SMA: −62.56%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.24%
Realised vol (20d, ann.): 71.5%
From 52-week high: −86.90%
From 52-week low: +1.89%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

5.00

+208.64% implied

Low 4.00Median 5.00High 6.00

Recommendation trend

Now1 / 1 / 0
1m ago1 / 1 / 0

Buy / hold / sell counts

Recent actions

DES

About Lipocine Inc.

Yahoo Finance profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Sector: Healthcare
Industry: Biotechnology
Employees: 14
Headquarters: Salt Lake City, UT, United States

SEAS

Seasonality · LPCN

2013–2026 · monthly returns

Strongest month Dec +8.01%Weakest month Oct −8.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	12.1	10.7	-19.8	-70.8	-3.4	13.8	-17.2	5.7	-1.8	-26.4			−79.8%
2025	-11.5	-28.9	3.6	4.1	2.1	-6.5	2.2	-9.9	-2.1	-6.7	29.3	133.4	+64.5%
2024	39.8	-2.3	36.5	-11.2	49.8	19.1	-36.8	-29.6	22.3	23.4	-18.1	7.5	+74.9%
2023	33.2	-14.9	-29.5	-18.2	4.8	8.9	-1.4	-20.5	-24.6	-14.4	-5.5	15.8	−58.8%
2022	2.9	20.6	11.4	-35.6	-8.0	-1.2	-5.9	-23.1	-22.4	-9.1	10.0	-11.6	−59.8%
2021	30.1	-10.2	-5.0	-6.6	-13.5	14.8	-5.7	-0.8	-16.8	-4.6	5.8	-9.9	−27.1%
2020	14.5	12.7	-3.4	15.4	65.0	37.9	22.2	-3.9	-4.7	-14.9	33.3	-15.0	+253.2%
2019	23.8	8.1	32.8	-20.3	-16.8	27.5	-3.1	55.6	-4.4	-4.3	-83.5	-13.5	−70.4%
2018	-61.6	43.9	-19.5	0.7	-23.4	10.2	0.8	13.7	-7.4	1.4	-2.9	-4.4	−62.2%
2017	-1.6	9.4	-1.5	8.7	-13.4	9.5	26.1	-25.4	5.0	-11.1	1.1	-3.6	−6.5%
2016	-29.9	11.5	0.5	-3.9	-10.4	-65.2	21.4	-8.7	32.3	-28.0	6.5	7.6	−71.5%
2015	5.5	30.5	-4.7	-3.8	6.2	21.7	44.1	19.1	-19.6	1.1	16.1	-6.9	+145.8%
2014	8.0	-10.2	-7.0	0.8	-13.6	-5.9	9.8	43.9	-36.6	-29.8	17.0	4.8	−36.2%
2013											-17.5	0.0	−17.5%

INSD

Insider Activity · LPCN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 27, 2026	Higuchi John WDirector	Purchase at price 2.16 per share.	12.6K	$27.13K
Apr 6, 2026	Higuchi John WDirector	Purchase at price 2.03 per share.	40K	$81.20K
Apr 5, 2026	Higuchi John WDirector	Purchase at price 2.05 per share.	123K	$252.15K
Apr 5, 2026	Patel Mahesh VChief Executive Officer	Purchase at price 2.03 per share.	25K	$50.75K
Apr 1, 2026	Patel Mahesh VChief Executive Officer	Purchase at price 9.25 per share.	25K	$231.25K

13F

Investors Holding LPCN

latest 13F filings of 29 followed managers

Investors holding LPCN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$177.2K	0.00%	69.21K	+80%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

LPCN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LPCN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lipocine Inc.

Seasonality · LPCN

Insider Activity · LPCN

Congress Trades · LPCN

Investors Holding LPCN

Investors Holding LPCN

Congress Trades · LPCN

Insider Activity · LPCN

Seasonality · LPCN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lipocine Inc.

Financial Snapshot

Earnings & Dividends

News